Takeda’s Founding Family To Resign From Company Board
This article was originally published in PharmAsia News
Japan's largest drug maker Takeda Pharmaceutical announced that one of the company's founding family members Kunio Takede will resign from his current position as chairman June 25. The position will be vacant for the time being. Kunio Takeda is the third son of the sixth generation of the Chobei Takeda family. Entering the company in 1962, Kunio Takeda was the only remaining Takeda family member sitting on the company's board. His resignation signals that the company is taking a decisively new business direction. (Click here for more - Japanese language
You may also be interested in...
Results from two trials confirm patients at high risk of bleeding treated with Abbott’s Xience stent can be safely treated with short regimens of dual antiplatelet therapy.
Through a licensing-out deal with ORIC for its EGFR/HER2 exon-20 inhibitor, South Korea's Voronoi hopes to gain from its new partner's commercialization experience in NSCLC. The alliance hopes to build a potentially best-in-class presence in a competitive landscape.
An expert panel at the virtual HLTH conference discussed the role of robotics in improving health and wellness in the health continuum. See what Darla Hutton, vice president of US marketing and customer hospital analytics at Intuitive Surgical, said about the future of robotics.